Incidence (≥10%) of grade 3 or 4 TEAEs and TEAEs related to uproleselan
| TEAE . | Patients, n (%) . | |
|---|---|---|
| All TEAEs . | TEAEs related to uproleselan . | |
| R/R AML treated with MEC (n = 66) | ||
| Febrile neutropenia | 39 (59) | 11 (17) |
| Thrombocytopenia | 23 (35) | 7 (11) |
| Anemia | 17 (26) | 5 (8) |
| Platelet count decreased | 12 (18) | 4 (6) |
| Neutropenia | 11 (17) | 3 (5) |
| Sepsis | 8 (12) | 3 (5) |
| WBC count decreased | 7 (11) | 1 (2) |
| Hypophosphatemia | 6 (9) | 1 (2) |
| Neutrophil count decreased | 4 (6) | 1 (2) |
| Pneumonia | 3 (5) | 0 |
| Newly diagnosed AML treated with 7 + 3 (n = 25) | ||
| Febrile neutropenia | 22 (88) | 3 (12) |
| Anemia | 6 (24) | 2 (8) |
| Platelet count decreased | 6 (24) | 0 |
| Thrombocytopenia | 6 (24) | 3 (12) |
| WBC count decreased | 5 (20) | 1 (4) |
| Hypokalemia | 4 (16) | 0 |
| Neutrophil count decreased | 4 (16) | 0 |
| Pneumonia | 4 (16) | 2 (8) |
| Respiratory failure | 4 (16) | 0 |
| Hypophosphatemia | 3 (12) | 1 (4) |
| Neutropenia | 3 (12) | 1 (4) |
| Pancytopenia | 3 (12) | 0 |
| Pulmonary edema | 3 (12) | 1 (4) |
| Sepsis | 2 (8) | 0 |
| TEAE . | Patients, n (%) . | |
|---|---|---|
| All TEAEs . | TEAEs related to uproleselan . | |
| R/R AML treated with MEC (n = 66) | ||
| Febrile neutropenia | 39 (59) | 11 (17) |
| Thrombocytopenia | 23 (35) | 7 (11) |
| Anemia | 17 (26) | 5 (8) |
| Platelet count decreased | 12 (18) | 4 (6) |
| Neutropenia | 11 (17) | 3 (5) |
| Sepsis | 8 (12) | 3 (5) |
| WBC count decreased | 7 (11) | 1 (2) |
| Hypophosphatemia | 6 (9) | 1 (2) |
| Neutrophil count decreased | 4 (6) | 1 (2) |
| Pneumonia | 3 (5) | 0 |
| Newly diagnosed AML treated with 7 + 3 (n = 25) | ||
| Febrile neutropenia | 22 (88) | 3 (12) |
| Anemia | 6 (24) | 2 (8) |
| Platelet count decreased | 6 (24) | 0 |
| Thrombocytopenia | 6 (24) | 3 (12) |
| WBC count decreased | 5 (20) | 1 (4) |
| Hypokalemia | 4 (16) | 0 |
| Neutrophil count decreased | 4 (16) | 0 |
| Pneumonia | 4 (16) | 2 (8) |
| Respiratory failure | 4 (16) | 0 |
| Hypophosphatemia | 3 (12) | 1 (4) |
| Neutropenia | 3 (12) | 1 (4) |
| Pancytopenia | 3 (12) | 0 |
| Pulmonary edema | 3 (12) | 1 (4) |
| Sepsis | 2 (8) | 0 |
MEC, mitoxantrone, etoposide, cytarabine; TEAE, Treatment emergent adverse events; WBC, white blood cell.